See more
What diseases is Regeneron used for?
Our clinical portfolio currently includes antibody candidates for over 30 types of cancer, including cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer, cervical, diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, ovarian, prostate cancers and many more.
How do you request Regeneron?
To request infusion of monoclonal antibodies and a medical team at your facility, you may call the 24-hour State Infusion Hotline at 1- 800- 742- 5990. An Infusion Specialist will record your information and process your request.
What is unique about Regeneron?
One of the things that's made Regeneron really unique is its willingness to invest in cutting edge technologies. We're one of the few companies in the world that go all the way from foundational discovery, to research, from research to development, to manufacturing and commercialization.
How do I contact Regeneron?
Medical inquiries Healthcare professionals, patients or caregivers may request specific product information, report an adverse event or report a product complaint for a Regeneron product to our Medical Information Department. Please call 1-844-REGN-MID (1-844-734-6643) for further information.
How long does Regeneron infusion last?
If you are receiving an intravenous infusion, the infusion will take 20 to 50 minutes or longer. o After the initial dose, if your healthcare provider determines that you need to receive additional doses of REGEN-COV for ongoing protection, the additional intravenous or subcutaneous doses would be administered monthly.
Can monoclonal antibodies make Covid worse?
Some possible risks from antibody treatment are: It may interfere with your body's ability to fight off a future infection of COVID-19. It may reduce your body's immune response to a vaccine for COVID-19.
Can Regeneron make Covid worse?
Monoclonal antibodies, such as REGENCOV, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. institutional setting (for example, nursing home or prisons).
Are there any side effects from Regeneron?
after infusion or injection, including fever, difficulty breathing, rapid or slow heart rate, tiredness, weakness or confusion. If these symptoms occur, contact your healthcare provider or seek immediate medical attention as some of these symptoms have required hospitalization.
Does Regeneron pay well?
Salaries at Regeneron Inc range from an average of $59,332 to $173,077 a year. Regeneron Inc employees with the job title Research Scientist make the most with an average annual salary of $101,422, while employees with the title Research Associate, Biotechnology make the least with an average annual salary of $73,273.
Is Regeneron FDA approved?
Regeneron's bid for COVID-19 drug's full approval hits snag as FDA extends review.
Where is Regeneron based?
Westchester County, New YorkRegeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.
Who is the CEO of Regeneron?
Leonard Schleifer (1988–)Regeneron Pharmaceuticals / CEODr. Schleifer has been recognized as one of Barron's Best CEOs and as an Ernst & Young Entrepreneur of the Year. He graduated from Cornell University and earned his MD and PhD in Pharmacology from the University of Virginia.
Is Regeneron a monoclonal antibody?
The US Food and Drug Administration (FDA) has revised the authorisations for two monoclonal antibody therapies of Regeneron and Eli Lilly to limit their usage.
What is in the Regeneron cocktail?
About the REGEN-COV Antibody Cocktail REGEN-COV (casirivimab and imdevimab) is a cocktail of two monoclonal antibodies that was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19, using Regeneron's proprietary VelocImmune® and VelociSuite® technologies.
Is Regeneron FDA approved?
Regeneron's bid for COVID-19 drug's full approval hits snag as FDA extends review.
Where is Regeneron Pharmaceuticals located?
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.
What is Regeneron's belief?
We believe that patients should have access to appropriate, evidence-based medicines to get them to the best health. Patients are singularly able to tell their story about access challenges and how these obstacles can impact their daily lives and health. Regeneron has supported advocacy training, distribution of access tools, town halls and coalition building for patients and caregivers so that they can have a greater chance for successful outcomes. To submit a request for funding, visit our grants portal.
What is compassionate use policy?
Our Compassionate Use Policy gives certain patients who have serious or life-threatening conditions access to a potentially beneficial medicine when no comparable or satisfactory alternative therapy options or clinical trials area available. Compassionate Use, also known as expanded access in the U.S., is an approved pathway that, by design, is meant for exceptional circumstances. Our Compassionate Use program has certain established criteria and each request is reviewed by Regeneron’s Compassionate Use Committee.
Is Regeneron a fast response?
To address emerging or rapidly spreading infectious diseases, Regeneron has applied our VelociSuite ® technologies in a ‘rapid response’ manner that parallel tracks certain steps and speeds hand-offs between groups in order to advance novel antibody treatments extremely quickly. We’ve been proud to apply our homegrown technologies and novel scientific approach to respond to public health challenges like Ebola, Middle East Respiratory Syndrome (MERS) and COVID-19.
